NCT03591653View on ClinicalTrials.gov

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks

PHASE3CompletedINTERVENTIONAL
Enrollment

291

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

October 30, 2019

Study Completion Date

November 26, 2019

Conditions
Non-erosive Reflux Disease
Interventions
DRUG

LXI-15028

The investigational products are administrated orally, once in the morning every day, and each dose includes one tablet of investigational products (LXI-15028 50mg active agent or placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 weeks.

DRUG

Placebo

Placebo

Trial Locations (1)

200120

Shanghai East Hospital, Shanghai

All Listed Sponsors
lead

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

INDUSTRY

NCT03591653 - A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks | Biotech Hunter | Biotech Hunter